Eli Lilly (LLY) Downgraded At Citigroup

Eli Lilly and Company (LLY) shares are down 1.50% in early trading after the drug maker was downgraded to ‘Neutral’ from ‘Buy’ by equities research analysts at Citigroup (C), in a research note issued to investors on Thursday. The firm however, raised its price price target on the stock to $68, up from their previous […] View the full post at: Eli Lilly (LLY) Downgraded At Citigroup Related posts: Citigroup Scores Occidental Petroleum to Buy Phibro From Citigroup for $250M Microsoft, Hewlett-Packard Increase Stock Buybacks